/Jiashitang: Jiashitang Pharmaceutical Co., Ltd. Simplified Equity Change Report

NEWS

Jiashitang: Jiashitang Pharmaceutical Co., Ltd. Simplified Equity Change Report

Shenzhen Stock Exchange

2026/02/05

Jiashitang Pharmaceutical Co., Ltd.

Simplified Equity Change Report

Listed company name: Jiashitang Pharmaceutical Co., Ltd.

Stock listing location: Shenzhen Stock Exchange

Stock abbreviation: Jiashitang

Stock code: 002462.SZ

One of the obligors for information disclosure: China Everbright Industrial (Group) Co., Ltd. Address: Room 915, 9th floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing. Correspondence address: Room 915, 9th floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing

Information disclosure obligor No. 2: China Everbright Healthcare Industry Co., Ltd. Address: Room 912, 9th floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing. Correspondence address: Room 912, 9th floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing.

Nature of change in shares: transfer by agreement (decrease)

February 2026

Statement

The information disclosure obligor prepares this report in accordance with the requirements of the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Measures for the Administration of Acquisitions of Listed Companies", "Guidelines on Information Disclosure Content and Format No. 15 of Companies Offering Securities to the Public - Equity Change Report" and other relevant laws, regulations and normative documents.

2. The information disclosure obligor has obtained the necessary authorization and approval to sign this report.

In accordance with the provisions of the "Securities Law", "Acquisition Management Measures" and "Standard No. 15", this report has fully disclosed the changes in the shares held by the information disclosure obligor in Jiashitang Pharmaceutical Co., Ltd. As of the signing date of this report, except for the information disclosed in this report, the information disclosure obligor has not increased or decreased its equity shares in Jiashitang through any other means.
This equity change still needs to go through relevant approval procedures before it can be implemented, including but not limited to: the Ministry of Finance of the People's Republic of China approved the transaction; the transaction passed the anti-monopoly review of the concentration of operators of the State Administration for Market Regulation; the Shenzhen Stock Exchange issued a confirmation opinion on matters related to the transaction.
Everbright Industrial, the obligor for information disclosure, holds 100% of the equity of Everbright Health. In accordance with the relevant provisions of the "Acquisition Management Measures", Everbright Industrial and Everbright Health are parties acting in concert.

6. This equity change did not cause Everbright Industrial and Everbright Health to violate their previous commitments.

Section 1 Introduction to the Information Disclosure Obligor

1. Everbright Industrial

(1) Basic situation of Everbright Industrial

Name: China Everbright Industrial (Group) Co., Ltd.

Registration address: Room 915, Floor 9, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing

Legal representative: Ma Xuequan

Registered capital: RMB 4.40 million

Unified social credit code: 91110000669900043B

Enterprise type: Limited liability company (sole proprietorship)

Main business scope: investment and investment management; business management consulting; investment consulting; real estate development; asset management; leasing of commercial facilities; technology development

Operation period: November 29, 2007 to November 28, 2107

Controlling shareholder: Everbright Group, 100% shareholding ratio

Mailing address: Room 915, 9th Floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing

(2) Basic information on the directors and principal persons in charge of Everbright Industrial

As of the signing date of this report, the basic information of Everbright Industrial’s directors and principal persons in charge is as follows:

Whether to obtain other

Long-term residence number Name Position Gender Nationality Country and region of residence

place of residence

retain rights

1 Hong Bo Chairman Male China No Beijing 2 Ye Zhenyong Vice Chairman, Executive Director Male China No Beijing 3 Xu Wenli Executive Director Male China No Beijing 4 Liao Shiye Executive Director Male China No Beijing 5 Pan Wenjie Executive Director Female China No Beijing 6 Qin Li Shareholder Representative Director Female China No Beijing 7 Sun Aijing Shareholder Representative Director Female China No Beijing 8 Ma Xuequan General Manager Male China No Beijing9 Wang Zaiqing Deputy General Manager Male China No Beijing

Whether to obtain other

Long-term residence number Name Position Gender Nationality Country and region of residence

Right of residence

10 Dai Yicong Deputy General Manager Male China No Beijing 11 Liu Liqin Assistant General Manager Male China No Beijing

(3) Everbright Industrial’s equity interests in other domestic or overseas listed companies reach or exceed 5% of the company’s issued shares

As of the signing date of this report, Everbright Industrial holds more than 5% of the shares of other listed companies domestically and overseas as follows:

Serial number Company name Listed exchange Direct and indirect voting rights 1 Lianlian Digital Technology Co., Ltd. Hong Kong Stock Exchange 5.07%

2. Everbright Health

(1) Basic information of Everbright Health

Name: China Everbright Healthcare Industry Co., Ltd.

Registration address: Room 912, 9th Floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing

Legal representative: Liao Shiye

Registered capital: RMB 485.3815 million

Unified social credit code: 91110105100008755D

Enterprise type: Limited liability company (sole proprietorship)

Main business scope: health consulting (except diagnosis and treatment activities subject to approval); health management (except diagnosis and treatment activities subject to approval); corporate headquarters management; business management; business management consulting; medical research (excluding diagnosis and treatment activities); technology development, technology promotion, technology transfer, technology consulting, technical services; education consulting; data processing; technology import and export, goods import and export, agency import and export; sales of Class I and II medical devices; sales of food; medical services; Internet information services; sales of Class III medical devices

Operation period: May 9, 2020 to no fixed period

Controlling shareholder: Everbright Industrial, 100% shareholding ratio

Mailing address: Room 912, 9th Floor, Building 3, No. 32 Jinfu Road, Shijingshan District, Beijing

(2) Basic information on directors and principal persons in charge of Everbright Health

As of the signing date of this report, the basic information of Everbright Health’s directors and principal persons in charge is as follows:

Whether to obtain other

Long-term residence number Name Position Gender Nationality Country and region of residence

place of residence

retain rights

1 Liao Shiye Executive Director Male China No Beijing 2 Pan Wenjie Deputy General Manager Female China No Beijing 3 Xie Hui Deputy General Manager Female China No Beijing

(3) Everbright Health’s equity interests in other domestic or overseas listed companies reach or exceed 5% of the company’s issued shares

As of the signing date of this report, with the exception of Jiashitang, Everbright Health has no equity interests in any other domestic or overseas listed companies reaching or exceeding 5% of the company's issued shares.

3. Concerted action relationship between information disclosure obligors

Everbright Industrial holds 100% equity of Everbright Health and is the controlling shareholder of Everbright Health. In accordance with the relevant provisions of the "Acquisition Management Measures", Everbright Industrial and Everbright Health are parties acting in concert. Everbright Industrial and Everbright Health are independent of each other in terms of assets and business, and there is no concerted action agreement. Both parties exercise the voting rights of Jiashitang shares in accordance with their respective corporate governance procedures. The equity relationships between Everbright Industrial, Everbright Health and Jiashitang are as follows:

Section 2 Purpose of Equity Change

1. Main changes in equity

On February 2, 2026, Everbright Industrial, Everbright Health and Tong Ren Tang Group signed a "Share Transfer Agreement". Everbright Industrial transferred the 41,180,805 A shares of Jiashi Tang directly held by it and the 41,876,431 A shares of Jiashi Tang indirectly held by Everbright Health to Tong Ren Tang Group.

After the completion of this equity change, Everbright Industrial and Everbright Health will no longer directly or indirectly hold any shares or voting rights in Jiashitang.

2. Purpose of equity changes

Everbright Industrial and Everbright Health took into account factors such as their actual development and future strategic direction, the comprehensive strength of the counterparty and market influence, and decided to transfer the shares of Jiashitang to Tongrentang Group. This transaction will help Everbright Industrial and Everbright Health further focus on the main business of health care, optimize resource allocation, concentrate on focusing on specializing in livelihood industries, promote high-quality development; actively fulfill the social responsibilities of central enterprises, and strengthen cooperation between the central and local governments.

As of the signing date of this report, except for this equity change, Everbright Industrial and Everbright Health have no plans to increase or continue to reduce their equity interests in Jiashitang in the next 12 months. If relevant equity changes occur, the information disclosure obligor will perform its information disclosure obligations in accordance with relevant laws and regulations.

Section 3 Equity Change Methods

1. Changes in shares held by information disclosure obligors in listed companies

(1) The number and proportion of shares owned before this equity change

Before this equity change, Everbright Industrial directly held 41,180,805 A shares of Jiashitang, accounting for 14.12% of the total issued shares of Jiashitang; and indirectly held 41,876,431 A shares of Jiashitang through Everbright Health, accounting for 14.36% of the total issued shares of Jiashitang; it held a total of 83,057,236 A shares of Jiashitang. shares, accounting for 28.48% of the total issued shares of Jiashitang.

(2) The number and proportion of shares owned after this equity change

After this equity change, Everbright Industrial and Everbright Health no longer directly or indirectly hold any shares or voting rights in Jiashitang.

(3) Equity control relationship of listed companies before and after this equity change

Before this equity change, the controlling shareholder of Jiashitang was Everbright Health, and the actual controller was Everbright Group. After this equity change, the controlling shareholder of Jiashitang was changed to Tongrentang Group, and the actual controller was changed to Beijing State-owned Assets Supervision and Administration Commission.

Changes in the relevant shareholders’ equity of Jiashitang are as follows:

Before changes in equity After changes in equity

shareholders

Number of shares held Shareholding ratio Number of shares held Shareholding ratio Everbright Health 41,876,431 shares 14.36% - -

Everbright Industrial 41,180,805 shares 14.12% - -

Tongrentang Group - - 83,057,236 shares 28.48%

2. The method of this equity change

The method of this equity change is transfer by agreement.

3. Main contents of the share transfer agreement

On February 2, 2026, Everbright Industrial, Everbright Health and Tong Ren Tang Group signed a "Share Transfer Agreement" with effective conditions. The first transferor is Everbright Health, the second transferor is Everbright Industrial, and the transferee is Tong Ren Tang Group.

The main terms of the agreement are as follows:

(1) Transaction entities and plans

Both parties agree that the transferor will transfer a total of 83,057,236 underlying shares of the listed company (accounting for 28.48% of the total shares of the listed company) to the transferee in accordance with the terms and conditions agreed in this agreement, and the transferee will transfer all the underlying shares held by the transferor in total in accordance with the terms and conditions agreed in this agreement. The details are as follows:

(1) Transferor 1 transfers the 41,876,431 tradable shares of the listed company it holds (accounting for approximately 14.36% of the total shares of the listed company) to the transferee by agreement transfer;

(2) Transferor 2 transferred the 41,180,805 tradable shares of the listed company (accounting for approximately 14.12% of the total shares of the listed company) held by it to the transferee by agreement transfer.

Unless otherwise agreed in this agreement, the gains and losses arising from the underlying shares from the base date to the delivery date shall be enjoyed or borne by the transferee, and no adjustment will be made to the total price of the underlying shares transferred due to the gains and losses during the above period.

After the transfer of the target shares is completed, the transferee shall enjoy shareholder rights and bear shareholder obligations stipulated in laws, regulations and the target company's articles of association in accordance with laws, regulations and the target company's articles of association.

(2) Transfer price

The transferor and the transferee unanimously agreed that the transfer price per share was RMB 17.59, and the total share transfer price was RMB 1,460,976,781.24. The transferee paid the transfer price corresponding to 41,876,431 shares (the "Transfer Price One") to the Transferor One, which is RMB 736,606,421.29, and the transfer price corresponding to the 41,180,805 shares (the "Transfer Price Two"), which was RMB 724,370,359.95, to the Transferor Two. In addition to the above share transfer price, neither the transferee nor the target company needs to pay any income to the transferor.

(3) Payment terms and payment arrangements

The payment arrangements for the share transfer price are as follows:

(1) The transferee shall pay 30% of the total share transfer price as a performance deposit to the account designated by the transferor within 5 working days after the signing of this share transfer agreement. Among them, 30% of the transfer price one is paid to the transferor one, and 30% of the transfer price two is paid to the transferor two. The transferee's performance bond payment obligation is independent of the effective conditions of this Agreement.

(2) The transferee should settle all the share transfer price no later than one working day before submitting the transaction to the Shenzhen Stock Exchange for compliance review, and the performance bond will automatically offset the transfer price (the remaining 70% of the transfer price after offset). That is, the transferee should pay 70% of the total share transfer price to the account designated by the transferor within 1 working day before submitting the transaction to the Shenzhen Stock Exchange for compliance review. Among them, 70% of the transfer price one is paid to the transferor one, and 70% of the transfer price two is paid to the transferor two.

(4) Effectiveness, modification and termination of the agreement

This Agreement shall be established upon signature and seal of all parties and their legal representatives or authorized representatives, and shall come into effect on the date when all the following conditions are met:

(1) All parties involved in this agreement have completed their internal approval procedures for this transaction and obtained all necessary authorizations to sign this agreement;

(2) All parties have obtained approval from the state-owned assets supervision and administration department for this transaction.

If before the implementation of this transaction, the laws and regulations applicable to this transaction are revised, other mandatory approval requirements are proposed or some administrative licensing matters are exempted, the effective conditions of this agreement will be adjusted based on the laws and regulations in effect at that time.

All parties to this agreement agree that if this agreement does not take effect within 90 days from the date of signing, the parties may negotiate to adjust relevant transaction arrangements and sign written agreements such as supplementary agreements.

This Agreement may be changed by consensus of all parties.

Any modifications to this Agreement must be agreed by all parties and made in the form of a signed written document, otherwise, they will not be binding on the other parties; any important or substantive modifications to this Agreement must obtain the required approvals, licenses, and filings with reference to the provisions of this Agreement before they can take effect; such modifications and additions to the Agreement in the form of written documents will become an integral part of this Agreement. Changes to the agreement do not affect the rights of the parties to claim damages.

If the relevant terms under this Agreement or the conditions related to this transaction are changed due to changes in relevant laws, regulations or policies, or in accordance with the requirements of government departments and/or securities trading regulatory agencies (including but not limited to the China Securities Regulatory Commission, the state-owned assets management department, the State Administration for Market Regulation, the Shenzhen Stock Exchange and the Clearing Company), the parties shall do their best to reach an agreement and accept such changes.

This agreement may be terminated when one of the following circumstances occurs:

(1) All parties may terminate this Agreement through consensus. In this case, this Agreement shall be terminated on the date on which all parties agree in writing to terminate this Agreement.

(2) The transaction described in this agreement has not passed the anti-monopoly review of the concentration of undertakings by the State Administration for Market Regulation, and this agreement shall be terminated from the date when the State Administration for Market Regulation issues a disapproval opinion. If the agreement is terminated due to the provisions of this paragraph, the parties shall not be liable for breach of contract by each other.

(3) The transaction described in this agreement has not passed the compliance review of Shenzhen Stock Exchange, and this agreement shall be terminated from the date when Shenzhen Stock Exchange issues a disapproval opinion. If the agreement is terminated due to the provisions of this paragraph, the parties shall not be liable for breach of contract by each other.

(4) During the transition period, if there are major adverse changes in the target company group that are not due to the transferee, resulting in the target company being delisted or subject to special treatment (ST), the transferee has the right to unilaterally terminate the agreement and will not be liable for breach of contract.

(5) Other circumstances under which the contract may be terminated under other laws and regulations.

(6) If this Agreement is terminated in accordance with the provisions of Articles (2), (3), (4), and (5) above, each party to this Agreement shall, in accordance with the principle of restoration to the original status, sign all documents and take all necessary actions or respond to the reasonable and legal requirements of the other party (the request shall not be unreasonably refused) to assist the other parties to return to the status of the signing date. If the transferee has paid the corresponding transfer price, the transferor first and transferor two shall sign all documents or take all actions in response to the reasonable and legal requirements of the other party (the request shall not be unreasonably refused). The full amount must be returned within 30 days. If the amount is not returned after 30 days, a penalty for delayed performance of the unpaid portion shall be paid at the rate of 0.05% for each overdue day (from the date of termination of the agreement to the date of repayment).

4. Rights restrictions on the shares to be transferred this time

As of the signing date of this report, there are no mortgages, pledges, judicial freezes or other restrictions on the transfer of the shares to be transferred. Except for the information disclosed in this report, there are no additional conditions for this share transfer and there is no supplementary agreement. The parties to the agreement have not reached other arrangements for the exercise of the voting rights of the shares. After the transfer is completed, the transferor no longer has any interest in the listed company.

5. Time and manner of changes in the shares held by the information disclosure obligor in the listed company

Time of change of equity: The date when the transfer parties complete the share transfer registration at the clearing company.

Method of equity change: Transfer by agreement.

6. This share transfer is subject to approval by relevant departments

The main approval procedures required for this transaction include:

The Ministry of Finance approves this transaction;
Beijing State-owned Assets Supervision and Administration Commission approved the transaction;
This transaction passed the anti-monopoly review on concentration of undertakings by the State Administration for Market Regulation;
Shenzhen Stock Exchange issued confirmation opinions on matters related to this transaction.

The information disclosure obligor will actively promote the submission of this transaction to the above-mentioned regulatory agencies for review and approval, and promptly announce the progress of the review and approval.

7. Investigation into the acquirer’s subject qualifications, credit standing, and intention to acquire the transfer

After this equity change, the information disclosure obligor will lose control of the listed company.

Before signing the "Share Transfer Agreement", the information disclosure obligor has conducted a reasonable investigation and understanding of Tong Ren Tang Group's subject qualifications, credit standing, transfer intention, etc., and is convinced that Tong Ren Tang Group has the qualifications as an acquirer of a listed company, has a reasonable intention to acquire control of a listed company, and has the ability to pay the transaction price in full and on time. There is no situation that prohibits the acquisition of a listed company as stipulated in Article 6 of the "Acquisition Management Measures".

Whether the transferor and its related parties have not paid off their liabilities to the listed company, failed to release the guarantee provided by the listed company for its liabilities, or have other circumstances that have harmed the interests of the listed company.

As of the signing date of this report, the information disclosure obligor and its related parties have no unpaid liabilities to the listed company, and there are no other situations that have not released the guarantee provided by the listed company for its liabilities or harmed the interests of the listed company.

Section 4. Purchase and sale of listed shares within the first six months. Everbright Industrial and Everbright Health did not buy or sell Jiashitang shares through centralized trading on the stock exchange in the six months before the date of this equity change.

Section 5 Other Major Matters

As of the signing date of this report, except for the matters disclosed in this report, the information disclosure obligor has no other information that must be disclosed to avoid misunderstandings about the contents of this report, and there is no other information that should be disclosed in accordance with the regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange but has not been disclosed.

Section 6 Documents for Inspection

1. File directory for reference

Business licenses of Everbright Industrial and Everbright Health;
List of directors and senior managers of Everbright Industrial and Everbright Health and their identity documents;
The "Share Transfer Agreement" signed by Everbright Industrial, Everbright Health and Tongrentang Group.

2. Preparation location

The above-mentioned documents for inspection are kept in the office of the Board of Directors of Jiashitang. Address: Building 1, No. 11, Hunan Road, Kunming, Haidian District, Beijing Tel: 010-88405868

Contact person: Chai Hao

Everbright Industrial Statement

I and the China Everbright Industrial (Group) Co., Ltd. I represent declare that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal liability for its authenticity, accuracy and completeness.

Information disclosure obligor: China Everbright Industrial (Group) Co., Ltd. (official seal)

Legal representative: (Signature)

Ma Xuequan

Signing date: year month day

Everbright Health Statement

I and the China Everbright Healthcare Industry Co., Ltd. I represent declare that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal responsibility for its authenticity, accuracy and completeness.

Information disclosure obligor: China Everbright Healthcare Industry Co., Ltd. (official seal)

Legal representative: (Signature)

Liao Shiye

Signing date: year month day

Schedule (Ebright Industrial)

Basic situation

Jiashitang Pharmaceutical Co., Ltd.

Listed company name Listed company location Beijing

company

Stock abbreviation Jiashitang Stock code 002462.SZ

Beijing Shijingshan District Gold Information Disclosure Obligor China Everbright Industrial (Group) Information Disclosure Obligor Note

Courtyard No. 3, No. 32, Fu Road Name of Limited Liability Company Registered Place

Room 915, 9th floor

Increase □ Decrease

☑

Equity shares

Are there any persons acting in concert? Yes ☑ No □ Changes in quantity remain unchanged, but changes in shareholders

Change □

Information disclosure obligor Information disclosure obligor Yes Yes No Is a listed company Yes □ No ☑ No Is the actual listed company Yes □ No ☑ The largest shareholder controller

Centralized trading through stock exchanges □ Agreement transfer

☑

Method of change of equity (can be administrative transfer or change of state-owned shares □ Indirect transfer □ Multiple choices) Obtaining new shares issued by a listed company □ Executing court ruling □ Inheritance □ Gift □

Others □

Direct shareholding:

Stock type: A shares ordinary shares

Information disclosure obligor Number of shares held: 41,480,805

Ownership before disclosure Shareholding ratio: 14.12%

The number and proportion of shares

Listed companies have issued indirect shares:

Shareholding ratio Stock type: A shares ordinary shares

Number of shares held: 41,876,431

Shareholding ratio: 14.36%

After this equity change, stock type: A shares ordinary shares

Information disclosure obligor Number of changes: 83,057,236

Change ratio of equity shares: 28.48%

Quantity and change ratio Number of shares held after change: 0

Owned by listed companies

Time: The date the transfer registration is completed

Interested shares change

Method: Agreement transfer

When and how to move

Yes No Fully disclosed

Not applicable

Source of funds

Information disclosure obligor

Is it planned to be planned in the future 12 Yes □ No ☑

Continue to increase holdings within the month

Information disclosure obligor

In the previous 6 months whether

Yes □ No

☑Buy and sell in the secondary market

The listed company's stock

If it involves the reduction of shares held by the controlling shareholder or actual controller of a listed company, the information disclosure obligor shall also explain the following:

Controlling shareholder or actual

When the controller reduces its holdings, it is

No Infringement of listing Yes□ No ☑Company and shareholders’ rights and interests

question

Controlling shareholder or actual

When the controller reduces its holdings, it is

No Existence Unliquidated Other

Liabilities to the company, not yet

Yes □ No

☑Lift the company from its liabilities

security provided by the debt, or

Those who harm the company's interests

other situations

This change in equity is

Yes No□

☑

Is approval required?

Yes □ No

☑

The main procedures that still need to be carried out: whether it has been approved

The Ministry of Finance approves this transaction;
Beijing State-owned Assets Supervision and Administration Commission approved the transaction;
This transaction passed the anti-monopoly review on concentration of undertakings by the State Administration for Market Regulation;
Shenzhen Stock Exchange issued confirmation opinions on matters related to this transaction.

Schedule (Ebright Health)

Basic situation

Jiashitang Pharmaceutical Co., Ltd.

Listed company name Listed company location Beijing

company

Stock abbreviation Jiashitang Stock code 002462.SZ

Beijing Shijingshan District Gold Information Disclosure Obligor China Everbright Healthcare Industry Information Disclosure Obligor Note

No. 3, Yard No. 32, Fu Road Name Industrial Co., Ltd. Registered address

Room 912, 9th floor

Increase □ Decrease

☑

Equity shares

Are there any persons acting in concert? Yes ☑ No □ Changes in quantity remain unchanged, but changes in shareholders

Change □

Information disclosure obligor Information disclosure obligor Yes No Yes No It is a listed company Yes ☑ No□ No It is the actual listed company Yes□ No ☑The largest shareholder controller

Centralized trading through stock exchanges □ Agreement transfer

☑

Others □

Information disclosure obligor

Ownership interests before disclosure Stock type: A shares ordinary shares

The number of shares and the number of shares held: 41,876,431

Issued shareholding ratio of listed companies: 14.36%

Share ratio

After this equity change, stock type: A shares ordinary shares

Information disclosure obligors Number of changes: 41,876,431

Change ratio of equity shares: 14.36%

Quantity and change ratio Number of shares held after change: 0

Owned by listed companies

Time: The date the transfer registration is completed

Interested shares change

Method: Agreement transfer

When and how to move

Yes No Fully disclosed

Not applicable

Source of funds

Information disclosure obligor

Is it planned to be planned in the future 12 Yes □ No ☑

Continue to increase holdings within the month

Information disclosure obligor

In the previous 6 months whether

Yes □ No

☑

Buy and sell in the secondary market

The listed company's stock

If it involves the reduction of shares held by the controlling shareholder or actual controller of a listed company, the information disclosure obligor shall also explain the following:

Controlling shareholder or actual

When the controller reduces its holdings, it is

No Infringement of listing Yes□ No ☑Company and shareholders’ rights and interests

question

Controlling shareholder or actual

When the controller reduces its holdings, it is

No Existence Unliquidated Other

Liabilities to the company, not yet

Yes □ No

☑Lift the company from its liabilities

security provided by the debt, or

Those who harm the company's interests

other situations

This change in equity is

Yes No□

☑

Is approval required?

Yes □ No

☑

The main procedures that still need to be carried out: whether it has been approved

The Ministry of Finance approves this transaction;
Beijing State-owned Assets Supervision and Administration Commission approved the transaction;
This transaction passed the anti-monopoly review on concentration of undertakings by the State Administration for Market Regulation;
Shenzhen Stock Exchange issued confirmation opinions on matters related to this transaction. (This page has no text, but is the signature and seal page of the "Jiashitang Pharmaceutical Co., Ltd. Simplified Equity Change Report" and its appendices)

Information disclosure obligor: China Everbright Industrial (Group) Co., Ltd. (Official seal) Legal representative: (Signature)

Ma Xuequan

Signing date: year month day

(This page has no text, but is the signature and seal page of the "Jiashitang Pharmaceutical Co., Ltd. Simplified Equity Change Report" and its appendices)

Information disclosure obligor: China Everbright Healthcare Industry Co., Ltd. (Official seal) Legal representative: (Signature)

Liao Shiye

Signing date: year month day